Vaxcyte surges following VAX-24 trial meeting primary endpoint, Tricida sinks following VALOR-CKD trial missing endpoint Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Vaxcyte (PCVX) up 72% after announcing its VAX-24 trial met the primary safety and tolerability objectives
UP AFTER EARNINGS/GUIDANCE -
- Hanesbrands (HBI) up 1%
- HNI Corporation (HNI) up 1%
- Kirby (KEX) up 2%
DOWN AFTER EARNINGS -
- Philips (PHG) down 1%
- Bank of Hawaii (BOH) down 1%
- Dorman Products (DORM) down 1%
LOWER -
- Tricida (TCDA) down 93% after announcing its VALOR-CKD trial did not meet its primary endpoint
- Tesla (TSLA) down 2% after Bloomberg reported Tesla has begun reducing starter prices for its Model 3 and Model Y cars by up to 9% in China
- Meta (META) down 1% after BofA analyst Justin Post downgraded Meta Platforms to Neutral from Buy with a price target of $150, down from $196
- FedEx (FDX) down 1% after Wells Fargo analyst Allison Poliniak-Cusic downgraded shares to Equal Weight with a price target of $160, down from $199
- Williams-Sonoma (WSM) down 3% after Jefferies analyst Jonathan Matuszewski downgraded the stock to Underperform from Hold with a price target of $100, down from $160
Symbols:
PCVX HBI HNI BOH KEX PHG DORM TCDA TSLA FDX WSM META Keywords: Fly Intel, Wall Street, Top Stories, Stocks